drugset / Trial / NCT00276172
Open-Label Natalizumab Safety Extension Study
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have completed natalizumab Studies C-1801, C-1802, or C-1803.
Timeline
- Start
- 2003-12
- Primary completion
- 2005-10
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | natalizumab | Monoclonal antibody | 300 mg | Intravenous |